Compare Elastic NV (ESTC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs BIO-TECHNE Corp — how do they compare? Elastic NV trades at $97.33 (market cap $10.00B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: Elastic NV and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Elastic NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and BIO-TECHNE Corp for 64 Days on average.
| ESTC | TECH | |
|---|---|---|
Market Cap | $10.00B | $11.36B |
Volume | 1,610,337 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $99.91 | $72.61 |
52-Week Low | $43.30 | $43.31 |
Typical Hold Time | 10 Days | 64 Days |
Enterprise Value | $9.14B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $96.44, up 3.59% today, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches in AI and observability platforms highlight innovation, while profitability metrics show improvement into 2026. The current price sits near resistance at $97, with RSI indicating potential overbought conditions short-term.
Outlook remains positive given earnings momentum and product expansion, but risks include high valuation multiples and insider selling. The consensus price target of $79.50 suggests caution, though bullish sentiment prevails with 65% buy ratings. Investors should weigh growth potential against execution risks in a competitive software market.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
